Catalyst Pharmaceuticals
(NASDAQ) CPRX
Catalyst Pharmaceuticals Financials at a Glance
Market Cap
$3.03B
Revenue (TTM)
$588.99M
Net Income (TTM)
$214.33M
EPS (TTM)
$1.68
P/E Ratio
14.74
Dividend
$0.00
Beta (Volatility)
1.00 (Average)
Dividend
$0.00
Beta (Volatility)
1.00 (Average)
Price
$24.82
Volume
0
Open
$24.93
Price
$24.82
Volume
0
Open
$24.93
Previous Close
$24.82
Daily Range
$24.67 - $25.12
52-Week Range
$19.05 - $26.58
Dividend
$0.00
Beta (Volatility)
1.00 (Average)
Price
$24.82
Volume
0
Open
$24.93
Previous Close
$24.82
Daily Range
$24.67 - $25.12
52-Week Range
$19.05 - $26.58
CPRX News
CPRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Catalyst Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
182
CEO
Richard John Daly, MBA
Website
www.catalystpharma.comHeadquarters
Coral Gables, FL 33134, US
CPRX Financials
Key Financial Metrics (TTM)
Gross Margin
85%
Operating Margin
44%
Net Income Margin
36%
Return on Equity
25%
Return on Capital
27%
Return on Assets
19%
Earnings Yield
6.78%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.03B
Shares Outstanding
122.12M
Volume
0
Short Interest
0.00%
Avg. Volume
1.24M
Financials (TTM)
Gross Profit
$501.74M
Operating Income
$257.78M
EBITDA
$321.01M
Operating Cash Flow
$208.67M
Capital Expenditure
$58.00K
Free Cash Flow
$208.61M
Cash & ST Invst.
$709.17M
Total Debt
$2.79M
Catalyst Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$152.61M
+7.6%
Gross Profit
$138.54M
+15.3%
Gross Margin
90.78%
N/A
Market Cap
$3.03B
N/A
Market Cap/Employee
$16.75M
N/A
Employees
181
N/A
Net Income
$52.70M
-5.8%
EBITDA
$81.06M
+12.1%
Quarterly Fundamentals
Net Cash
$706.38M
+37.3%
Accounts Receivable
$128.27M
+95.9%
Inventory
$37.17M
+90.2%
Long Term Debt
$2.35M
-15.6%
Short Term Debt
$437.00K
+8.7%
Return on Assets
19.36%
N/A
Return on Invested Capital
26.86%
N/A
Free Cash Flow
$44.86M
-36.6%
Operating Cash Flow
$44.89M
-36.7%